IPSEF News and Press, Ipsen Sa Ord From 10/11/18

Ipsen Canada Appoints Ed Dybka as General Manager Canada NewsWire MISSISSAUGA, ON, Oct. 11, 2018 MISSISSAUGA, ON , Oct. 11, 2018 /CNW/ - Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dy...

Exelixis (NASDAQ: EXEL ) announces that its partner Ipsen ( OTCPK:IPSEF ) received a positive opinion from the CHMP, for CABOMETYX (cabozantinib) tablets as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. More n...

The following slide deck was published by Ipsen S.A. ADR in conjunction with their 2018 Q2 earnings Read more ...

Ipsen ( OTCPK:IPSEF ) and BioLabs to open a life science co-working facility called the ‘Ipsen Innovation Center - BioLabs’ (IPSEN-ICB) within the company’s new North America global hub in Kendall Square, Cambridge, Massachusetts, to foster development of new ther...

Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise $80 million from the sale of its common stock in a U.S. IPO, according to an amended registration statement . The company is developing a pipeline of treatment candidates for rare endocrine disorders. CRNX has achieved pro...

Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . Crinetics is a clinical-stage pharmaceutical company that develops and manufactures pharmaceuticals for endocrine diseases and en...

Exelixis (NASDAQ: EXEL ) is up  5%  premarket, albeit on only 100 shares, in response to its announcement that the European Commission has approved commercialization partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application for CABOMETYX (cabozantinib) for the first-li...

Ipsen S.A. ( OTCPK:IPSEF ): Q1 Revenue of €510.3M (+16.5% Y/Y) Press Release More news on: Ipsen S.A., Ipsen S.A. ADR, Earnings news and commentary, Healthcare stocks news,

Exelixis (NASDAQ: EXEL ) announces that the European Medicines Agency (EMA) has accepted for review collaboration partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application seeking approval for CABOMETYX (cabozantinib) for previously treated patients with advanced hepatocellular ...

Exelixis (NASDAQ: EXEL ) announces that commercialization partner Ipsen ( OTCPK:IPSEY )( OTCPK:IPSEF ) has received a positive opinion from the European Commission's Committee for Medicinal Products for Human Use (CHMP) backing approval for CABOMETYX (cabozantinib) for the first-line treat...